Microbiome Drugs Market: Rising prevalence of autoimmune diseases to drive the market

Microbiome drugs are used for metabolism and immunity. In a human body, microbes are used as a factory to produce drug, a modulator for dug action, a vehicle for drug delivery, and sometimes itself is consider as a drug. Microbiomes are used for the treatment of different diseases such as autoimmune diseases and inflammatory bowel diseases. The chemicals produced by microbiota are nonfood derivatives chemical molecules and vitamin B12. The microbiome of an average adult can weigh at least 3 pounds. The gastrointestinal (GI) microbiome is the most important microbiome in the human body. When the GI microbiome shifts away from a healthy state, it is known as dysbiosis or pathobiosis. The high effectiveness and less adverse effects have motivated researchers and pharmaceutical and biotechnology companies to shift toward microbiome drugs. Several companies are focusing on partnership and collaboration for research activities. In 2014, Pfizer partnered with Second Genome, a biotechnology firm in South San Francisco, California, to study the microbiomes of about 900 people. The boom in partnerships and investments for new microbiome-derived drugs and therapies is projected to create a competitive market place for other therapeutic products.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26126

Drivers such as increasing research and development activities, large number of pipeline drugs, growing acceptance among people, and rising prevalence of autoimmune diseases, cancer, and gastrointestinal diseases are expected to propel the growth of the global microbiome drugs market. In 2016, according to the Centers for Disease Control and Prevention in the U.S., about 1 to 1.3 million people suffered from inflammatory bowel diseases. In addition, factors such as technological advancement, government initiatives, and increasing collaboration between pharmaceutical companies for new drug development are likely to drive the market growth. In 2016, White House Office of Science and Technology Policy collaborated with Federal agencies and private-sector stakeholders for National Microbiome Initiative (NMI) to advance the understanding of microbiomes for the development of useful applications in health care, food production, and environmental restoration. However, lack of awareness about the use of microbiome drugs may hinder the global microbiome market growth.

Request for Analysis of COVID-19 Impact on Microbiome Drugs Market –


The global microbiome drugs market has been segmented by product type, application, distribution channel, and geography. In terms of product type, the market is classified into probiotics, prebiotics, small molecules, and biological drugs. In terms of application, the market is classified into autoimmune diseases, inflammatory bowel diseases, cancer, and others. In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Pre book Microbiome Drugs Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=26126&ltype=S

Geographically, the global market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global market for microbiome drugs due to technological advancement, availability of advanced facilities for microbiome product manufacture, awareness among the people, and high health care expenditure. Europe is the second leading market due to increasing number of research and development activities and presence of a large number of biotechnology companies. Asia Pacific is expected to expand at a high growth rate due to presence of high target patient pool, rising disposable income, growing prevalence of diabetes, increasing government initiatives, and growing awareness among people. According to Asian Diabetes Prevention Initiatives, 60% of global diabetes population live in Asia. Emerging regions such as Latin America and Middle East & Africa are projected to create a large opportunity for the global microbiome drug market due to rise in awareness, increase in public and private health care insurance coverage, government initiatives, and growth in healthcare investment.

Top of Form

Ask for Discount :


Key players operating in this market include Seres Therapeutics; MaaT Pharma; Enterome Bioscience; MicroBiome Therapeutics LLC; Ritter Pharmaceuticals; Rebiotix, Inc.; Second Genome; and OpenBiome.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.


Mr. Rohit Bhisey
Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Back to news